Roche Holding AG (ROG) Stock Forecast & Price Target

Compare

57 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

ROG Analyst Ratings

Hold

4 Buy

4 Hold

2 Sell

Based on 10 analysts giving stock ratings to

Roche

Holding AG

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

ROG Stock 12 Month Forecast

Average Price Target

CHF337.90

▼(-3.65% Downside)

Based on 10 Wall Street analysts offering 12 month price targets for Roche Holding AG in the last 3 months. The average price target is CHF337.90 with a high forecast of CHF400.00 and a low forecast of CHF230.00. The average price target represents a -3.65% change from the last price of CHF350.70.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"229":"CHF229","272":"CHF272","315":"CHF315","358":"CHF358","401":"CHF401"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":400,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">CHF400.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":337.9,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">CHF337.90</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":230,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">CHF230.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[229,272,315,358,401],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"May<br/>2025","6":"Aug<br/>2025","9":"Nov<br/>2025","12":"Feb<br/>2026","25":"Feb<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,350.7,354.4923076923077,358.2846153846154,362.0769230769231,365.86923076923074,369.66153846153844,373.45384615384614,377.24615384615385,381.03846153846155,384.83076923076925,388.62307692307695,392.4153846153846,396.2076923076923,{"y":400,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,350.7,349.7153846153846,348.7307692307692,347.74615384615385,346.76153846153846,345.7769230769231,344.7923076923077,343.80769230769226,342.8230769230769,341.8384615384615,340.8538461538461,339.86923076923074,338.88461538461536,{"y":337.9,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,350.7,341.4153846153846,332.1307692307692,322.8461538461538,313.5615384615385,304.2769230769231,294.9923076923077,285.7076923076923,276.4230769230769,267.13846153846157,257.8538461538461,248.56923076923078,239.2846153846154,{"y":230,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":276.844,"date":1738368000000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 19</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":289.621,"date":1740787200000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 18</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":292.4,"date":1743465600000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 18</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":269.3,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 14</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":264.7,"date":1748736000000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 15</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":260.7,"date":1751328000000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 16</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":257.1,"date":1754006400000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 14</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":260.2,"date":1756684800000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 16</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":282.3,"date":1759276800000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 16</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":258.9,"date":1761955200000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 20</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":309,"date":1764547200000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 13, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 17</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":328.2,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 19, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 9</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":350.7,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 17, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price TargetCHF400.00

Average Price TargetCHF337.90

Lowest Price TargetCHF230.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Matthew Weston

UBS

CHF296.71

Buy

-15.39%

Downside

Reiterated

01/30/26

Analysts Offer Insights on Healthcare Companies: Teladoc (NYSE: TDOC), Roche Holding AG (Other OTC: RHHVF) and Zimmer Biomet Holdings (NYSE: ZBH)

Graham Parry

Citi

CHF400

Buy

14.06%

Upside

Reiterated

01/30/26

Bank of America Securities Initiates a Buy Rating on Roche Holding AG (RHHVF)

Justin Smith

Bernstein

CHF400

Buy

14.06%

Upside

Reiterated

01/29/26

Analysts Offer Insights on Healthcare Companies: Roche Holding AG (Other OTC: RHHVF), Halozyme (NASDAQ: HALO) and Elevance Health (NYSE: ELV)

Richard Vosser

J.P. Morgan

CHF350

Hold

-0.20%

Downside

Reiterated

01/29/26

Analysts Offer Insights on Healthcare Companies: Insmed (NASDAQ: INSM) and Roche Holding AG (Other OTC: RHHVF)

David Evans

Kepler Capital

CHF315

Buy

-10.18%

Downside

Reiterated

01/29/26

Analysts Conflicted on These Healthcare Names: Revolution Medicines (NASDAQ: RVMD), Roche Holding AG (Other OTC: RHHVF) and Incyte (NASDAQ: INCY)

Emmanuel Papadakis

Deutsche Bank

CHF325

Hold

-7.33%

Downside

Reiterated

01/28/26

Analysts Offer Insights on Healthcare Companies: Roche Holding AG (Other OTC: RHHVF) and Genmab (NASDAQ: GMAB)

Michael Leuchten

Jefferies

CHF230

Sell

-34.42%

Downside

Reiterated

01/27/26

Roche Holding AG (RHHVF) Gets a Sell from Jefferies

James Quigley

Goldman Sachs

CHF365

Hold

4.08%

Upside

Reiterated

01/27/26

Roche Holding AG (RHHVF) Gets a Hold from Goldman Sachs

Luisa Hector

Berenberg Bank

CHF320

Hold

-8.75%

Downside

Reiterated

01/16/26

Analysts Have Conflicting Sentiments on These Healthcare Companies: HCA Healthcare (NYSE: HCA), Vertex Pharmaceuticals (NASDAQ: VRTX) and Roche Holding AG (Other OTC: RHHVF)

Sarita Kapila

Morgan Stanley

CHF290

Sell

-17.31%

Downside

Reiterated

12/02/25

Analysts' Opinions Are Mixed on These Healthcare Stocks: Apogee Therapeutics (NASDAQ: APGE), Regeneron (NASDAQ: REGN) and Roche Holding AG (Other OTC: RHHVF)

Yihan Li

Barclays

CHF275

Hold

-21.59%

Downside

Reiterated

10/24/25

Barclays Sticks to Their Hold Rating for Roche Holding AG (RHHVF)

Elmar Kraus

DZ BANK AG

Buy

―

Reiterated

10/23/25

DZ BANK AG Keeps Their Buy Rating on Roche Holding AG (RHHVF)

Rajesh Kumar

HSBC

CHF285→CHF320

Buy

-8.75%

Downside

Upgraded

10/01/25

HSBC upgrades Roche Holding AG (RHHVF) to a Buy

Peter Verdult

Exane BNP Paribas

CHF300

Buy

-14.46%

Downside

Initiated

04/16/25

BNP Paribas Exane Starts Roche Holding (ROG:SW) (RHHBY) at OutperformBNP Paribas Exane analyst Peter Verdult initiates coverage on Roche Holding (ROG:SW) (OTC: RHHBY) with a Outperform rating and a price target of CHF300.00.

Analyst Type

Any

Human Analysts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Matthew Weston

UBS

CHF296.71

Buy

-15.39%

Downside

Reiterated

01/30/26

Analysts Offer Insights on Healthcare Companies: Teladoc (NYSE: TDOC), Roche Holding AG (Other OTC: RHHVF) and Zimmer Biomet Holdings (NYSE: ZBH)

Graham Parry

Citi

CHF400

Buy

14.06%

Upside

Reiterated

01/30/26

Bank of America Securities Initiates a Buy Rating on Roche Holding AG (RHHVF)

Justin Smith

Bernstein

CHF400

Buy

14.06%

Upside

Reiterated

01/29/26

Analysts Offer Insights on Healthcare Companies: Roche Holding AG (Other OTC: RHHVF), Halozyme (NASDAQ: HALO) and Elevance Health (NYSE: ELV)

Richard Vosser

J.P. Morgan

CHF350

Hold

-0.20%

Downside

Reiterated

01/29/26

Analysts Offer Insights on Healthcare Companies: Insmed (NASDAQ: INSM) and Roche Holding AG (Other OTC: RHHVF)

David Evans

Kepler Capital

CHF315

Buy

-10.18%

Downside

Reiterated

01/29/26

Analysts Conflicted on These Healthcare Names: Revolution Medicines (NASDAQ: RVMD), Roche Holding AG (Other OTC: RHHVF) and Incyte (NASDAQ: INCY)

Emmanuel Papadakis

Deutsche Bank

CHF325

Hold

-7.33%

Downside

Reiterated

01/28/26

Analysts Offer Insights on Healthcare Companies: Roche Holding AG (Other OTC: RHHVF) and Genmab (NASDAQ: GMAB)

Michael Leuchten

Jefferies

CHF230

Sell

-34.42%

Downside

Reiterated

01/27/26

Roche Holding AG (RHHVF) Gets a Sell from Jefferies

James Quigley

Goldman Sachs

CHF365

Hold

4.08%

Upside

Reiterated

01/27/26

Roche Holding AG (RHHVF) Gets a Hold from Goldman Sachs

Luisa Hector

Berenberg Bank

CHF320

Hold

-8.75%

Downside

Reiterated

01/16/26

Analysts Have Conflicting Sentiments on These Healthcare Companies: HCA Healthcare (NYSE: HCA), Vertex Pharmaceuticals (NASDAQ: VRTX) and Roche Holding AG (Other OTC: RHHVF)

Sarita Kapila

Morgan Stanley

CHF290

Sell

-17.31%

Downside

Reiterated

12/02/25

Analysts' Opinions Are Mixed on These Healthcare Stocks: Apogee Therapeutics (NASDAQ: APGE), Regeneron (NASDAQ: REGN) and Roche Holding AG (Other OTC: RHHVF)

Yihan Li

Barclays

CHF275

Hold

-21.59%

Downside

Reiterated

10/24/25

Barclays Sticks to Their Hold Rating for Roche Holding AG (RHHVF)

Elmar Kraus

DZ BANK AG

Buy

―

Reiterated

10/23/25

DZ BANK AG Keeps Their Buy Rating on Roche Holding AG (RHHVF)

Rajesh Kumar

HSBC

CHF285→CHF320

Buy

-8.75%

Downside

Upgraded

10/01/25

HSBC upgrades Roche Holding AG (RHHVF) to a Buy

Peter Verdult

Exane BNP Paribas

CHF300

Buy

-14.46%

Downside

Initiated

04/16/25

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Roche Holding AG

3 Months

xxx

Success Rate

14/16 ratings generated profit

Average Return

+9.20%

reiterated a xxx

rating 5 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 87.50% of your transactions generating a profit, with an average return of +9.20% per trade.

1 Year

Matthew WestonUBS

Success Rate

11/11 ratings generated profit

Average Return

+26.25%

reiterated a buy rating 4 days ago

Copying Matthew Weston's trades and holding each position for 1 Year would result in 100.00% of your transactions generating a profit, with an average return of +26.25% per trade.

2 Years

xxx

Success Rate

8/8 ratings generated profit

Average Return

+43.96%

reiterated a xxx

rating 3 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 100.00% of your transactions generating a profit, with an average return of +43.96% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

ROG Analyst Recommendation Trends

Rating

Oct 25

Nov 25

Dec 25

Jan 26

Feb 26

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, ROG has received 12 Buy Ratings, 17 Hold Ratings, and 4 Sell Ratings. ROG average Analyst price target in the past 3 months is 337.90.

Each month's total comprises the sum of three months' worth of ratings.

ROG Financial Forecast

ROG Earnings Forecast

Next quarter’s earnings estimate for ROG is CHF10.94 with a range of CHF10.94 to CHF10.94. The previous quarter’s EPS was CHF8.38. ROG beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.43% of the time in the same period. In the last calendar year ROG has Performed in-line its overall industry.

ROG Sales Forecast

The previous quarter’s earnings for ROG were CHF30.57B.

ROG Stock Forecast FAQ

What is CH:ROG’s average 12-month price target, according to analysts?

Based on analyst ratings, Roche Holding AG’s 12-month average price target is 337.90.

What is CH:ROG’s upside potential, based on the analysts’ average price target?

Currently there's no upside potential for CH:ROG, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is Roche Holding AG a Buy, Sell or Hold?

Roche Holding AG has a consensus rating of Hold, which is based on 4 buy ratings, 4 hold ratings and 2 sell ratings.

What is Roche Holding AG’s share price target?

The average share price target for Roche Holding AG is 337.90. This is based on 10 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst share price target is CHF400.00 ,and the lowest forecast is CHF230.00. The average share price target represents -3.65% Decrease from the current price of CHF350.7.

What do analysts say about Roche Holding AG?

Roche Holding AG’s analyst rating consensus is a Hold. This is based on the ratings of 10 Wall Streets Analysts.

How can I buy shares of Roche Holding AG?

To buy shares of CH:ROG, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.

Roche Holding AG (ROG) Stock Forecast & Price Target

ROG Analyst Ratings

ROG Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Roche Holding AG

ROG Analyst Recommendation Trends

ROG Financial Forecast

ROG Earnings Forecast

ROG Sales Forecast

ROG Stock Forecast FAQ

Detailed List of Analyst Forecasts